Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- Conditions
- Age Related Macular DegenerationChoroidal Neovascularization
- Interventions
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 531
- Registration Number
- NCT00331864
- Locations
- 🇨🇭
Novartis - 64 sites in 11 countries, Basel, Switzerland
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
- Conditions
- Influenza
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 100
- Registration Number
- NCT00329966
- Locations
- 🇮🇹
Ufficio Igiene e Sanità Pubblica di Lanciano, ASL, Via S. Spaventa, 37, Lanciano, Italy
🇮🇹Dipartimento di Medicina e Scienze dell'Invecchiamento Università G. D'AnnunzioVia dei Vestini, Chieti, Italy
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
- Conditions
- Influenza
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00329927
- Locations
- 🇮🇹
Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via dei Vestini, Chieti, Italy
🇮🇹Ufficio Igiene e Sanità Pubblica di Lanciano, Via S. Spaventa, 37, Lanciano, Italy
A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy
- Conditions
- Hypertension
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 894
- Registration Number
- NCT00327145
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2279
- Registration Number
- NCT00327587
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, E. Hanover, New Jersey, United States
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2009-01-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00325429
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2007-05-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00325117
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
- Conditions
- Influenza Disease
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 100
- Registration Number
- NCT00316615
- Locations
- 🇮🇹
G. D'Annunzio University, Chieti, Italy
🇮🇹Office of Hygiene and Public Health, ASL Lanciano, Lanciano, Italy
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.
- Conditions
- Influenza
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2006-09-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00316628
- Locations
- 🇮🇹
G. D'Annunzio University, Chieti, Italy
🇮🇹Office of Hygiene and Public Health, ASL Lanciano, Lanciano, Italy
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
- Conditions
- Pre-diabetes
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00312130
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States